Who's in favor of translational cell therapy for stroke: STEPS forward please?

Michael Chopp, Gary K. Steinberg, Douglas Kondziolka, Mei Lu, Tonya M. Bliss, Yi Li, David C. Hess, Cesario V. Borlongan

Research output: Contribution to journalComment/debate

39 Scopus citations

Abstract

A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.

Original languageEnglish (US)
Pages (from-to)691-693
Number of pages3
JournalCell Transplantation
Volume18
Issue number7
DOIs
StatePublished - Nov 9 2009

    Fingerprint

Keywords

  • Cellular therapy
  • Clinical translation
  • Stem cell transplantation
  • Tissue regeneration

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Chopp, M., Steinberg, G. K., Kondziolka, D., Lu, M., Bliss, T. M., Li, Y., Hess, D. C., & Borlongan, C. V. (2009). Who's in favor of translational cell therapy for stroke: STEPS forward please? Cell Transplantation, 18(7), 691-693. https://doi.org/10.3727/096368909X470883